[Comparative evaluation of the therapeutic effect of oxyferriscorbone in peptic ulcer].
D015083:2,3-Diketogulonic Acid / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000496:Alloxan / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D013400:Sugar Acids / Q000627:therapeutic use*; D013997:Time Factors
D000897:Anti-Ulcer Agents; D004338:Drug Combinations; D005290:Ferric Compounds; D010276:Parasympatholytics; D013400:Sugar Acids; D015083:2,3-Diketogulonic Acid; C008747:oxyferriscorbone; D000496:Alloxan; D010208:Papaverine; D007501:Iron
Sravnitel'naia otsenka lechebnofo éffekta oksiferriskorbona pri iazvennoĭ bolezni.